However, because non-infectious inflammation is present in the early and progressive stages in most Pkd1 mutant mouse models and ADPKD patients, it is necessary to understand the roles and underlying mechanisms that drive inflammatory response in ADPKD, which may facilitate the development of novel therapeutic strategy for ADPKD treatment. This evidence concerns the gene PKD1 and autosomal dominant polycystic kidney disease.